SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effects while inducing weight loss without hypoglycemia.
Plodkowski, R. A., McGarvey, M. E., Huribal, H. M., Reisinger-Kindle, K., Kramer, B., Solomon, M., & Nguyen, Q. T. (2015). SGLT-2 inhibitors for the treatment of type 2 diabetes mellitus. Federal Practitioner, 32(Suppl. 11), 10S-17S.
Originally published in Federal Practitioner, 32(Suppl. 11), 10S-17S. Reprinted with permission. This material can be found here.